Economic Environment
Global Economic Overview 1
The global economy demonstrated notable resilience throughout CY 2025, sustaining a stable growth rate of 3.4% and a stabilised inflation rate of 4.1% despite persistent geopolitical friction and widespread trade uncertainty. While changing international relations and logistical vulnerabilities generated short-term pressures. Nations leveraged temporary bilateral agreements to realign logistics networks to mitigate these operational challenges.
Although the broader export market experienced a general moderation as countries strategically accelerated frontloaded shipments, overall trade activity remained moderate as organisations actively restructured their sourcing networks. Escalating tensions in West Asia continues to pose challenges across supply chain networks, particularly through rising crude oil prices that have escalated petrochemical costs. Despite these headwinds, a significant volume of trade activity was driven by technology-led exports, which successfully maintained the overall growth momentum across nations.
Central banks in major economies implemented calibrated monetary policies to safeguard macro economic stability, effectively managing the ongoing volatility across various international financial markets during the year. Additionally, strategic updates to trade and production systems further stimulated economic activity across multiple key regions. International trade continued to help reduce the income gap between different countries.
Outlook
The global economic outlook is projected to maintain a steady trajectory, with global GDP growth moderating to approximately 3.1% in CY 2026 before improving slightly to 3.2% in CY 2027. This anticipated growth will be underpinned by sustained investments in technology, digital infrastructure and manufacturing.
An expected improvement in business sentiment and a reduction in trade pressures will provide significant growth. Ongoing efforts to diversify global supply chains should stimulate business activities across multiple regions. These strategic shifts could likely strengthen the financial performance over the medium term.
Despite this positive momentum, navigating political tensions in West Asia are expected to remain a significant hurdle for world markets. Shifting trade dynamics will continue to influence the overall global economic outlook moving forward.
Indian Economic Review 2
The Indian economy broadly demonstrated sustained resilience with an estimated growth rate of 7.7% in FY 2026. 3 This expansion was supported by vibrant economic activity, robust consumption and steady investment momentum. Additionally, strategic government initiatives targeting banking sector stability and corporate supply chain optimisation have strengthened Indias macroeconomic foundation. This upward trajectory was bolstered by an adaptable service sector and progressive tax rationalisation efforts.
India maintains its position as a preferred global destination for greenfield ventures, driven by sustained Foreign Direct Investment (FDI) inflows. Price stability remains a key achievement, with CPI inflation moderating to approximately 3.4% in March 2026, a result of proactive monetary interventions by the Reserve Bank of India and steady domestic demand offsetting food and energy fluctuations. 3
Business sentiment continues to be strong, with primary indicators reflecting expansion across the manufacturing and services sectors. The governments strategic emphasis on expanding domestic production within critical and emerging industries positions India for its future growth path. These encouraging advancements continue to bolster industrial momentum, establishing a solid framework for enduring macroeconomic advancement in the coming periods.
Outlook 4
Indias real GDP expansion is projected to reach approximately 6.6% during FY 2026-27, driven by resilient domestic demand, strengthening consumption patterns and sustained infrastructure investments. 5 Medium-term growth will be further reinforced by strategic government initiatives in manufacturing, industrial development and logistics optimisation. Urban consumption is positioned for additional gains, driven by streamlined GST frameworks and a flourishing services sector. The governments commitment to public infrastructure persists, while private business investments are anticipated to rebound, supported by elevated factory capacity utilisation, robust credit availability and encouraging financial conditions.
For FY 2026-27, CPI inflation is estimated at 5.1% 6 .This trajectory faces primary upward pressures from recent increases in global energy prices driven by geopolitical tensions, which have already triggered upward price adjustments in select fuel categories. Additionally, commodity prices may influence export activity and are expected to adjust in tandem with evolving global economic pressures.
Industry Overview
Global Pharmaceutical Industry 7
The global pharmaceutical sector continues to demonstrate substantial expansion, with the total aggregate market currently valued between $1.2 trillion and $1.6 trillion in 2025.
During CY 2025, premier multinational pharmaceutical corporations sustained strong growth momentum. These industry leaders generated approximately $800 billion in aggregate revenue. This performance underscores robust commercial execution and resilient demand across key portfolios.
The macroeconomic landscape is characterised by high granularity and strategic specialisation. Rather than broad-based competition, a concentrated cohort of leading enterprises dominates the market. These firms capture significant market share by developing targeted, high-value therapies for specific disease categories on a global scale.
Global pharmaceutical market expansion is fundamentally driven by specialised product pipelines tailored to precise international medical needs. Increased global healthcare spending and aging demographics ensure steady demand for novel treatments. Consequently, continuous scientific innovation and strategic therapeutic focus remain the core growth drivers for modern international companies, collectively shaping competitive dynamics across the sector.
The global pharmaceutical landscape is characterised by escalating medicine usage and rising international expenditures. Government policies across various nations are actively reshaping drug pricing and patient access to treatments. Ongoing trends in disease management and therapeutic innovation steadily drive-up global medicine consumption.
Geographically, China leads global market expansion, while mature economies such as North America experience much slower growth. Developed markets primarily drive spending increases through innovative therapeutics for oncology and chronic diseases. Concurrently, most geographic regions are transitioning toward advanced therapies that carry significantly higher financial costs. 8
Worldwide Total Prescription Drug Sales (2015-2030E)
Outlook 9
Over the next few decades, the pharmaceutical industry is positioned to assume a significantly broader and more transformative role within the healthcare ecosystem. Driven by scientific breakthroughs, global medicine consumption is expected to approach 4 trillion daily doses by 2030. The sector is increasingly equipped to develop targeted treatments and definitive cures for complex diseases that historically lack enviable the rapeutic options, aided by advanced scientific developments. Simultaneously, the convergence of molecular biology, computational chemistry and AI-enabled discovery is compressing traditional R&D timelines to accelerate the delivery of novel medicines. This shift, ushering in a new era of precision, prevention and personalisation, arrives at a critical macroeconomic inflection point.
United States healthcare expenditures have surpassed $ 5 trillion annually, expanding at a rate of 8% per year. Market insights reveal that 65% of consumers now fundamentally prioritise preventative methodologies over reactive treatments, a behavioural shift that is projected to reallocate an estimated $ 1 trillion in annual healthcare spending over the next ten years. Moving forward, sustained industry leadership will belong to organisations operating at the frontier of biology, technology and data. By strategically deploying artificial intelligence to enhance human judgment and accelerate institutional learning, companies that align their capital and capabilities with this transformative vision will ultimately define the next era of pharmaceutical leadership.
Global API Market 10
The global active pharmaceutical ingredients (API) market is projected to expand significantly from an estimated $ 245.67 billion in 2026 to $ 348.61 billion by 2031, achieving a CAGR of 7.25%. While fundamental demand remains robust due to aging demographics, escalating chronic diseases and a rise in biological drug approvals, manufacturers must navigate profitability through continuous-flow technology, merchant production and domestic on-shoring initiatives.
Governments across India, the U.S. and the EU provided over $ 4 billion in tax credits and Production Linked Incentives between 2024 and 2026 to reduce geographic supply chain vulnerabilities, successfully concentrating new capacity within localised hubs. Consequently, contract development and manufacturing organisations (CDMOs) outpaced captive facilities by adopting continuous-flow and mini-plant systems, which lower capital requirements and accelerated turnaround times for mid-volume APIs.
API Market Growth
Market Size ($, billion)
| CY 2026 | 245.67 |
| CY 2030 P | 348.61 |
P - Projected
Source: API Market Size and Share - Mordor Intelligence
Small Molecule API Market 11
The global small molecule API market has reached a substantial size of $ 207.67 billion in 2025. This market is expected to experience strong growth in the coming years, expanding to $ 223.59 billion in 2026 at a CAGR of 7.7% and further reaching $ 299.83 billion by 2030 at a CAGR of 7.6%.
A prominent growth driver for this industry is the rising chronic and non-communicable diseases worldwide, such as cardiovascular conditions, metabolic disorders and cancer, which heavily increases the global demand for therapeutic interventions. Additionally, the industry is driven by factors such as the historic growth of generic drug manufacturing, patent expirations of major blockbuster drugs, an expansion of pharmaceutical manufacturing bases in Asia, a rising demand for oncology medications and the steady growth of contract development and manufacturing outsourcing.
Small Molecule API Market Outlook
Market Size ($ billion)
| CY 2025 | 207.67 |
| CY 2026 P | 223.59 |
| CY 2027 P | 299.83 |
P - Projected
Source: Small Molecule Active Pharmaceutical Ingredient Market Report 2026
Indian Pharmaceutical Industry 12
Indias pharmaceutical Industry ranks third globally by volume and eleventh by value, with its domestic market valued at $ 60 billion in 2025. The industry comprises more than 3,000 companies operating across 10,500 manufacturing units nationwide. India is widely recognised as the Pharmacy of the World, for providing assured quality at affordable prices.
Indias growth trajectory demonstrates deepening integration into global pharmaceutical supply chains. It also hosts the highest number of USFDA-approved manufacturing plants outside the United States. Indian manufacturers supply approximately 60% of UNICEFs total vaccine requirements globally.
India has recently concluded several trade agreements that significantly expand pharmaceutical market access globally. The India-UK Comprehensive Economic and Trade Agreement, signed in July 2025, is particularly noteworthy. Under this deal, 56 pharmaceutical tariff lines will receive zero-duty market access in the UK. The India-EU Free Trade Agreement opens a market valued at approximately $ 572.3 billion for Indian pharmaceuticals. The India-New Zealand FTA, concluded in December 2025, provides zero-duty access across around 90 tariff lines. These pacts are anticipated to deepen healthcare trade and substantially support the ongoing expansion of Indias pharmaceutical manufacturing ecosystem.
The governments Biopharma SHAKTI initiative, proposed in the Union Budget 2026-27, marks an ambitious step forward. It carries a total outlay of 10,000 crore spread over the next five years.
The initiative aims to position India as a global biopharmaceutical manufacturing hub of considerable significance. It will establish 3 new and upgrade 7 existing National Institutes of Pharmaceutical Education and Research. Additionally, a network of over 1,000 accredited clinical trial sites will be created across India. FDI inflows into drugs and pharmaceuticals reached 13,193 crore for FY 2025-26, reflecting strong confidence in Indias pharmaceutical future.
Growth Drivers
Cost-Efficient Manufacturing and Generic Drug Leadership
Indias low-cost manufacturing model has established it as the undisputed global leader in generic medicines. The country supplies around 20% of the worlds generic medicines across 60 therapeutic categories. This pricing advantage, backed by a skilled scientific workforce, makes Indian medicines preferred worldwide.
Government-Led Production Linked Incentive Schemes
PLI schemes have been transformative in strengthening domestic manufacturing and reducing Indias import dependence considerably. The Pharmaceuticals PLI alone has generated total sales of 3,16,797 crore and employed approximately 97,000 persons. Investments under the scheme reached
40,890 crore. These schemes have collectively avoided imports worth 3,591 crore, meaningfully building Indias self-reliance.
Indian Pharmaceutical
Market Size ($ billion)
| 2025 | 60 |
| 2030 F | 130 |
F - Forecasted
Source: Arc Advisory - Indias Pharmaceutical Industry
Outlook
Indias pharmaceutical market is projected to expand to approximately $ 130 billion by 2030, with the primary catalysts being Indias robust export capabilities and proactive government initiatives designed to stimulate market growth. Through these strengths, India has firmly established itself at the forefront of the global industry and is poised to maintain its prominent position as a global leader.
Looking ahead, the Indian pharmaceutical industry is well-positioned to maintain a growth rate of 7-9%. This growth is driven by high domestic demand, steady exports and a clear shift toward advanced areas like complex generics, biosimilars and specialty products. Government policies are actively driving this growth and improving quality compliance.
At the same time, national innovation is gaining momentum from the rising interest in the Promotion of Research and Innovation in Pharma MedTech scheme, as well as global licensing deals and strategic acquisitions that show growing confidence in Indian
To reach its full potential and move from manufacturing improvements to discovering new drugs, the industry is focusing on three key areas:
Securing long-term risk capital
Promoting deeper collaboration between industry and academia
Expanding domestic production capacity to reduce supply chain risks and remain globally competitive
Company Overview
SMS Pharmaceuticals is a prominent pharmaceutical manufacturer in India with advanced, state-of-the-art production facilities in Hyderabad and Vizag, boasting capacities of 120 KL and 3,000 KL for niche small-scale and large-scale manufacturing, respectively. Exhibiting high strategic agility amid evolving industry dynamics, the Company has successfully positioned itself as a global player in API manufacturing, aided by strong market presence, robust backward-integrated operations, an expert research and manufacturing workforce and a sophisticated industrial infrastructure.
The Company has successfully transitioned from a single-product, single-unit operation into an integrated, multi-location enterprise with a well-diversified portfolio spanning over multiple therapeutic segments. Over its years of sustained operational excellence, the Company has attained Export House status, successfully expanded its commercial footprint and established a robust presence across international markets. Presently operating as a publicly listed entity, the Company maintains a steadily expanding client base across both domestic and international markets. Backed by a dual-faceted production capability.
Product Portfolio
SMS Pharmaceuticals has a well-diversified product portfolio, which contributes to its strong foothold in regulatory markets. The products can be categorised as:
| Therapeutic areas | Key Products | Category |
| Anti- inflammatory | Ibuprofen | High-volume |
| Anti-Retro Viral (ARV) | Tenofovir | High-volume |
| Anti-diabetic | Sitagliptin, Empagliflozin, Dapagliflozin, Vildagliptin | High-value |
| Anti-migraine | Sumatriptan, Rizatriptan, Eletriptan | High-value |
| Anti-ulcer | Famotidine, Pantoprazole | High-volume |
| Anti-erectile dysfunction | Tadalafil, Sildenafil, Vardenafil | High-value |
| Anti-epileptic | Levetiracetam, Perampanel, Lamotrigine | High-value |
| Anti-anginal | Ranolazine | High-value |
Competitive Advantage
Structural cost advantage:
Through strategic backward integration, the Company has achieved exceptional cost efficiency across its product portfolio. This optimised manufacturing framework and robust supply channel ensure that SMS Pharmaceuticals maintains a highly competitive edge over other industry players
Extensive research and development:
Supported by an elite panel of scientists, the Company continuously innovates to enhance and diversify its product portfolio. These premium APIs are the direct result of an unwavering corporate commitment to research excellence and state-of-the-art manufacturing processes.
Manufacturing excellence:
Driven by robust operational efficiency and deep domain expertise, the Company utilises its advanced manufacturing capabilities as a primary engine for growth. The commissioning of the 3,000 KL Vizag facility amplifies this scaling prowess and substantially strengthens overall capacity.
Geographic diversification:
The Company commands a resilient global footprint, distributing its specialised products across an extensive network of over 75 countries. Notably, international markets generate 85% of total revenues, underscoring the deep global trust placed in SMS Pharmaceuticals.
Business Overview
Domestic API Business
SMS Pharmaceuticals is a strategically positioned domestic enterprise that leverages its robust manufacturing capabilities and strategic integration to develop and commercialise market-standard APIs. This core segment drives approximately 96% of the companys total sales, boasting a diverse portfolio of over 55 products across 14 therapeutic categories. Notably, the company stands as a leading global exporter of anti-inflammatory, anti-retroviral (ARV) and anti-diabetic therapeutics. It also features Asias largest automated production facility for ibuprofen, an operation that has secured multiple international regulatory clearances, including three distinct approvals from the USFDA, alongside certifications from the KFDA, CDSCO and PMDA.
International Business
SMS Pharmaceuticals specialises in niche molecules and holds a strong position in the global API market with high-quality, regulatory-compliant drugs. It holds 140 plus Drug Master Files (DMFs) with agencies like USFDA, PMDA, CSDSCO and KFDA. With the initiation of ibuprofen production at the Vizag facility, SMS has captured a relatively large share of the European market. The Company generates the majority of its revenue from regions such as Europe, North America and Asia (excluding India). With strong manufacturing processes and a competent workforce, SMS Pharmaceuticals continues to enhance its reputation among European customers while striving to strengthen its presence worldwide.
| 55+ | 88% | 75+ | 140+ |
| Product Portfolio | Revenue from regulatory markets | Countries associated with The business of the Company | Drug Master Files |
Financial Review
Consolidated financial performance for the year ended 31 st March, 2026.
| Particulars | FY 2025-26 | FY 2024-25 | YoY Changes (in %) |
| Net Revenue from Operations (Net of Excise) ( in crore) | 886.87 | 782.75 | 13% |
| EBITDA ( in crore) | 179.63 | 145.21 | 23% |
| PAT ( in crore) | 101.98 | 69.14 | 47% |
| EPS (in ) | 11.15 | 8.16 | 37% |
| Net worth ( in crore) | 785.81 | 639.64 | 22.85% |
Financial Ratios
(As at 31 st March, 2026 vs. 31 st March, 2025)
| Particulars | As at 31 st March, 2026 | As at 31 st March, 2025 | % Change |
| Debtors Turnover Ratio | 4.23 | 3.56 | 19% |
| Inventory Turnover Ratio | 2.79 | 3.02 | -8% |
| Interest Coverage Ratio (Times) | 7.77 | 7.89 | -2% |
| Current Ratio | 1.81 | 1.71 | 6% |
| Debt Equity Ratio | 0.45 | 0.46 | -7% |
| Operating Profit Margin | 20.21% | 18.68% | 8% |
| Net Profit Margin | 9.88% | 8.74% | 13% |
| Return on Net Worth | 12.03% | 11.00% | 9% |
Outlook
SMS Pharmaceuticals maintains a strong business outlook centred on capacity expansion, portfolio broadening, and deeper backward integration. The company expects anti-inflammatory and ARV APIs, alongside new product introductions, to remain critical drivers of long-term growth and profitability. Backed by its on-track 280 crore capital expenditure program set for completion by FY27 and a target of 10 dynamic regulatory submissions (including DMF and CEP filings), SMS Pharma is structurally well-positioned.
Strategy
SMS Pharmaceuticals continues to reinforce its market position through a robust, backward-integrated operating framework. To accelerate future growth, the Company is executing a planned capital expenditure of 280 crore. This ongoing strategic investment is fully expected to be completed by the conclusion of FY 27.
Strategic CAPEX allocation: Demonstrating a disciplined allocation strategy, wherein 87% of this capital is dedicated to brownfield expansion projects, while the remaining portion of the expenditure is earmarked for greenfield initiatives and crucial strategic land acquisition. This targeted capital outlay 66 primarily focuses on scaling up the Companys existing active pharmaceutical ingredient base. Crucially, a strategic portion of this capital is allocated toward advanced research and development for peptides. This specialised peptide pipeline is projected to be fully operational by FY 29. Management views this emerging therapeutic vertical as a growth driver over the next 12 to 24 months.
Extensive Research and Development: Complementing this infrastructure growth, SMS Pharmaceuticals maintains an expertise-driven research and development wing. The specialised team works extensively toward advanced process optimisation and sustainable long-term margin protection. Through these innovation initiatives, the Company has secured more than 35 proprietary process patents. These technical milestones grant the organisation substantial leverage by driving superior operational efficiency across manufacturing lines. To aggressively accelerate this pipeline, the Company intends to double its financial investment in research and development over the next 15 months.
Expanding global foothold: Backed by technical capabilities, the Company maintains a strong commercial foothold in stringent regulatory API markets. To fortify this regulatory position, the Company is targeting 20 new Drug Master File (DMF) and Certificate of Suitability (CEP) filings over the next
24 months. Additionally, to expand its global footprint, the Company established a strategic joint venture with Chemo Iberica SA. The partnership with the Spanish pharmaceutical player aims to develop generic formulas and commercialise advanced APIs. Together, these aligned operational and financial milestones position the Company for sustainable and profitable future expansion.
Research and Development
SMS Pharmaceuticals is accelerating its global market presence and driving innovation through expertise-driven research and development capabilities.
A specialised research panel consisting of more than 100 scientists continuously delivers manufacturing excellence and ensures high-quality across product categories. To date, these focused innovation efforts have successfully secured more than 35 proprietary process patents.
The Company has established a formidable global regulatory presence by filing more than 140 Drug Master Files. Building on this momentum, the team completed around 12 regulatory submissions during FY26. Aiming to capitalise on this global growth, the enterprise aims to double its research investment over the next 15 months. This capital infusion will directly support to achieve the target of filing 20 new regulatory dossiers in the next 24 months.
The research cell has been extensively expanded through a strategic joint venture with Chemo Iberica SA. This collaborative partnership with the Spanish pharmaceutical giant has effectively added valuable new generic products to the pipeline. On a laboratory scale, the Company has already developed and validated an array of sophisticated therapeutic molecules. These internal advancements span vital categories including anti-hypertensive, antipsychotic, ulcerative colitis, anti-inflammatory, anti-depressant and anti-diabetic therapeutics. Together, these robust pipeline developments position the organisation for sustainable long-term growth across critical global healthcare markets.
100 +
Scientists in R&D
12
Regulatory submissions during FY26
35
Proprietary Process Patents
Human Resources (HR)
SMS Pharmaceuticals remains committed to promote a supportive, growth-centric workplace that recognizes its workforce as its most valuable asset. The Companys human resource strategy prioritizes continuous learning, comprehensive training programs, and proactive skill-enhancement initiatives. By emphasizing work-life balance, maintaining a healthy corporate culture, and adhering to rigorous health and safety standards, SMS Pharmaceuticals ensures that every employees contribution is valued. HR plays a strategic role in aligning individual career aspirations with broader corporate objectives, driving high levels of engagement and productivity. As of March 31, 2026, the Companys operational workforce exceeded 1600 personnel.
Quality and Compliance
SMS Pharmaceuticals maintains rigorous global quality management systems to ensure its products consistently align with or exceed stringent market specifications. Through continuous operational improvements and strict adherence to regulatory compliance standards, the Company successfully preserves its market-leading position for exceptional product quality and corporate compliance.
Health, Safety and Environment (HSE)
SMS Pharmaceuticals prioritizes employee well-being and operational safety by strictly complying with international standards. The Companys integrated management system is certified to both ISO 14001 (Environmental) and ISO 45001 (Occupational Health and Safety) standards. At Unit II, regular training programs enhance workforce emergency preparedness. The facility is fully equipped with essential firefighting equipment, personal protective gear, and dedicated first-aid squads, complemented by on-site medical personnel and an on-premises ambulance for rapid emergency response.
The Company is dedicated to reducing its environmental footprint by deploying advanced technologies and optimizing resource consumption. SMS Pharmaceuticals has successfully commissioned Zero Liquid Discharge (ZLD) plants across all operational locations and actively collaborates with suppliers to uphold matching environmental standards. Driven by environmental awareness and continuous employee training, the Companys innovative green chemistry initiatives have earned formal recognition through the prestigious Indo-US Green Chemistry Network Award.
Corporate Social Responsibility (CSR)
SMS Pharmaceuticals is dedicated to driving meaningful social and environmental impact through its structured CSR framework. Prioritizing underprivileged communities, the Company promotes inclusive regional development by enhancing access to essential healthcare and quality education. Key initiatives include the construction of educational infrastructure, support for healthcare capacity building, community development infrastructure facilities in rural areas, and the stimulation of local livelihoods. Through these targeted interventions, SMS Pharmaceuticals actively contributes to holistic community advancement and sustainable, shared prosperity across its operational footprints.
Internal Control Systems
SMS Pharmaceuticals has implemented robust internal control systems and processes across all of its financial and business activities. The Companys strong control framework supports its corporate governance, providing assurance of accurate record maintenance and credible reporting of financial and business information, compliance with relevant regulations, safeguarding of assets against misuse or loss, adequate authorisation of transactions and adherence to corporate policies. To put these practices into writing, the Company has an exhaustive delegation of authority document for authorisation of expenditures and revenues and is committed to continuously enhancing its controls. The Audit Committee is central to this function. It regularly examines internal procedures, advises corrective actions when necessary and reports to the Board of Directors periodically on major findings, thus aiding in the provision of an effective and secure environment of controls.
Cautionary Statement
The management of SMS Pharmaceuticals Ltd. has carefully prepared and takes full responsibility for the financial statements included in this report. These statements comply with Indian Accounting Standards and other relevant regulations, reflecting well-considered judgments and estimates.
Some sections of this report may contain forward-looking statements intended to help investors understand potential future opportunities and make informed investment decisions. However, these statements are subject to risks and uncertainties, such as regulatory changes, political or economic developments, technological challenges and other factors that could result in actual outcomes differing from those projected.
While the Company aims to make prudent assumptions, it cannot guarantee the realisation of these forward-looking statements. Various factors, including economic conditions affecting demand, supply and pricing in domestic and international markets, changes in regulations and other unforeseen events, may impact the Companys performance. Readers should consider these factors when evaluating the statements. The Company is not obligated to publicly update or revise any forward-looking statements based on new information, future events, or other circumstances.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.